Vir Biotechnology Soars 10.14% Ahead of Morgan Stanley Conference

On August 27, 2025, Vir Biotechnology's stock surged by 10.14% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Vir Biotechnology's CEO, Dr. Marianne De Backer, is set to participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9. This event provides a platform for the company to showcase its latest developments and strategic initiatives, which could further boost investor confidence and drive stock performance.

The company's participation in such a high-profile conference underscores its commitment to innovation and leadership in the biotechnology sector. As Vir Biotechnology continues to make strides in its research and development efforts, investors are likely to remain optimistic about the company's future prospects.